Bioimmune Synergies India Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 14-12-2024
- Paid Up Capital ₹ 5.00 M
as on 14-12-2024
- Company Age 5 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 5.00 M
as on 14-12-2024
- Revenue 170.93%
(FY 2022)
- Profit 112.45%
(FY 2022)
- Ebitda 0.26%
(FY 2022)
- Net Worth 6.12%
(FY 2022)
- Total Assets 78.07%
(FY 2022)
About Bioimmune Synergies India
The Company is engaged in the Agriculture Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 5.00 M.
The company currently has active open charges totaling ₹5.00 M.
Abhilash Avulla, Tejesvi Avulla, and Venkata Alluri serve as directors at the Company.
- CIN/LLPIN
U24100TG2019PTC131108
- Company No.
131108
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
06 Mar 2019
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Bioimmune Synergies India?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Abhilash Avulla  | Director | 13-Mar-2023 | Current |
| Tejesvi Avulla | Director | 13-Mar-2023 | Current |
| Venkata Alluri | Additional Director | 03-Nov-2021 | Current |
Financial Performance of Bioimmune Synergies India.
Bioimmune Synergies India Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 170.93% increase. The company also saw a substantial improvement in profitability, with a 112.45% increase in profit. The company's net worth moved up by a moderate rise of 6.12%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Bioimmune Synergies India?
In 2022, Bioimmune Synergies India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Sentience Intelligence Solutions Private LimitedActive 6 years 7 months
Abhilash Avulla is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of India Creation Date: 06 Feb 2024 | ₹5.00 M | Open |
How Many Employees Work at Bioimmune Synergies India?
Unlock and access historical data on people associated with Bioimmune Synergies India, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Bioimmune Synergies India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Bioimmune Synergies India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
